Last reviewed · How we verify
20vPCV
20vPCV is a pneumococcal conjugate vaccine that stimulates immune responses against 20 serotypes of Streptococcus pneumoniae to prevent pneumococcal disease.
20vPCV is a pneumococcal conjugate vaccine that stimulates immune responses against 20 serotypes of Streptococcus pneumoniae to prevent pneumococcal disease. Used for Prevention of pneumococcal disease in adults aged 18 years and older, Prevention of invasive pneumococcal disease, pneumococcal pneumonia, and otitis media.
At a glance
| Generic name | 20vPCV |
|---|---|
| Also known as | Prevnar 20 |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide antigens (20 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
20vPCV combines polysaccharide antigens from 20 serotypes of S. pneumoniae conjugated to a protein carrier, enhancing immunogenicity and inducing both T-cell dependent antibody responses and cellular immunity. This broader serotype coverage aims to provide protection against a wider range of pneumococcal infections compared to earlier generation pneumococcal conjugate vaccines.
Approved indications
- Prevention of pneumococcal disease in adults aged 18 years and older
- Prevention of invasive pneumococcal disease, pneumococcal pneumonia, and otitis media
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease (PHASE3)
- Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |